Johnson & Johnson Overview
Pro stress-test →Johnson & Johnson achieved full-year 2025 revenue of $94.2 billion with accelerated momentum in both Innovative Medicine and MedTech segments. CEO Joaquin Duato described 2025 as a catapult year fueled by the strongest portfolio and pipeline in company history, driven by medical innovation across oncology, immunology, neuroscience, cardiovascular, surgery, and vision.
Strategic Profile
Pro stress-test →J&J has double-digit growth potential by decade's end, underpinned by a diversified base of 28 billion-dollar products and rapid expansion in oncology, immunology, and cardiovascular markets. The company recently announced its 63rd consecutive annual dividend increase, maintaining its prestigious title as a Dividend King.
Competitive Landscape
Pro stress-test →J&J operates across oncology, immunology, neuroscience in Innovative Medicine, and cardiovascular, surgery, and vision in MedTech. Primary competitors include pharmaceutical giants like Pfizer, Merck, and AbbVie in the drug segment, and Medtronic, Abbott, and Boston Scientific in medical devices.
Industry Context
Johnson & Johnson operates in Pharmaceuticals & Medical Devices (Healthcare/Life Sciences).
Key facts
Founded: 1886 · Headquarters: New Brunswick, US · Employees: ~135,000 · Revenue: $94.2B · Market cap: ~$450B